1. Telomeres and COVID-19;Aviv;FASEB Journal,2020
2. Imbalanced host response to SARS-CoV-2 drives development of COVID-19;Blanco-Melo;Cell,2020
3. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020;Centers for Disease Control and Prevention Coronavirus Disease 2019 Response Team;Morbidity and Mortality Weekly Report,2020
4. Targeting the “cytokine storm” for therapeutic benefit;D’Elia;Clinical and Vaccine Immunology: CVI,2013